Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
Research indicates β-blockers may reduce the risk of motor diagnosis and slow symptom progression in Huntington's disease, ...
U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may ...
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
A patient in the UK has received a new therapy for Huntington’s disease, which experts hope could slow progression of the fatal illness. Huntington’s is an inherited condition that is caused ...
William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today.Pick the best stocks and ...
Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 ...
A common heart drug may slow the progression of Huntington's disease (HD), according to a new study by University of Iowa ...